Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi

(2013) Massimo Federico et al.   JOURNAL OF CLINICAL ONCOLOGY

Selection of First-Line Therapy for Advanced Follicular Lymphoma

(2013) Oliver W. Press et al.   JOURNAL OF CLINICAL ONCOLOGY

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

(2013) Mathias J Rummel et al.   LANCET

A Canadian perspective on bendamustine for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma

(2012) R. Van der Jagt et al.   Current Oncology

Bendamustine Produces Durable Responses With an Acceptable Safety Profile in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma

(2010) Bruce D. Cheson et al.   Clinical Lymphoma Myeloma & Leukemia

Follicular Lymphoma in the United States: First Report of the National LymphoCare Study

(2009) Jonathan W. Friedberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia

(2009) Wolfgang U. Knauf et al.   JOURNAL OF CLINICAL ONCOLOGY

Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study

(2008) Jonathan W. Friedberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma

(2008) K. Sue Robinson et al.   JOURNAL OF CLINICAL ONCOLOGY